κ-Opioid receptor activation suppresses triple-negative breast cancer progression by inducing urea cycle dysfunction and mitochondrial damage in vitro and in mice. Comment on Br J Anaesth 2025; 135: 1803–15

The article presents the authors' response to a critical commentary by Wang and colleagues regarding their recent research published in the British Journal of Anaesthesia. The research focuses on κ-opioid receptor (KOR) activation as a potential therapeutic strategy against triple-negative breast cancer (TNBC). The authors welcome the critique and engage in discussion about the translational potential, mechanisms of action, and safety profile of κ-opioid agonists. The response addresses important considerations regarding the applicability of laboratory research findings to clinical practice. The authors appreciate the colleagues' interest in their work and remain open to discussion on relevant scientific questions.